Objective: Ospemifene, a new drug indicated for the treatment of vulvovaginal atrophy, has completed phase III clinical trials. A condition affecting millions of women worldwide, vulvovaginal atrophy has long been treated with estrogen therapy. Estrogen treatment carries with it risks of thromboembolism, endometrial proliferative effects, and breast cancer promotion. In this study, we test the effects of three dosing levels of ospemifene in both the prevention and treatment of breast cancer in the MTag.Tg mouse model.
V ulvovaginal atrophy (VVA) manifests as vaginal dryness, itching, and dyspareunia. It affects millions of postmenopausal women worldwide. Treatment options include lubricants, moisturizers, or estrogen, administered locally or systemically. Estrogen products for the treatment of VVA include vaginal rings, creams, tablets, and transdermal patches. Common adverse effects of oral estrogen therapy include increased breast density (which may lead to abnormal mammograms and biopsies), tenderness, nausea, 1 weight gain, 2 fluid retention, and vaginal bleeding. 3 In addition, estrogen usage may expose women to health risks including gallbladder and thromboembolic diseases, 4<12 coronary heart disease, breast cancer, and stroke. 13, 14 The safety of local estrogens is not fully understood, since they also increase serum estrogen levels. 15<27 The safety of hormone therapy use in women with a history of cancer is controversial, 28, 29 and estrogen treatments address only the symptoms of VVA, not the underlying cause of the condition.
Selective estrogen receptor modulators (SERMs) are nonsteroidal compounds that bind to the estrogen receptor (ER) and can exert both agonistic and antagonistic effects in tissuespecific settings. Sites expressing ER include breast, bone, brain, uterine, and genitourinary tissues. 30 SERMs such as tamoxifen have been useful in the treatment and prevention of breast cancer, leading to reduced rates of recurrence and death, but produce undesirable adverse effects including VVA.
The development of new SERMs, which do not induce vasomotor and VVA adverse effects but are still efficacious, would provide progress in therapies and enhance the quality of life for women with breast cancer and postmenopausal women as a whole. Ospemifene, a triphenylethylene derivative, was originally developed as an osteoporosis drug but has been prepared for submission to the Food and Drug Administration as a treatment for VVA. Unlike estrogen, which carries endometrial proliferation and thromboembolic risks, ospemifene treatment is not associated with such events. 1,2,14,31<34 The impact of ospemifene treatment on breast cancer development, however, has not been fully examined. Ospemifene has been tested in several animal models but none with intact immune systems or without reliance on the chemical induction of cancer. In this study, we use the immunologically intact MTag.Tg transgenic mouse model, which produces synchronized, multifocal mammary tumors, to test the effect of ospemifene on ER-positive breast tumors in vivo.
METHODS

Chemicals
Ospemifene (Ophena; chemical name: Z-2-[4-(4-chloro-1,2diphenyl-but-1-enyl)phenoxy]ethanol) was manufactured by Lipomed AG (Arlesheim, Switzerland). 4-Hydroxyospemifene (4-OH ospemifene) and toremifene were provided by the Orion Corporation, Orion-Pharma, Espoo, Finland. All reagents including hexane, methanol, butanol, and water were highpressure liquid chromatography graded and purchased from Fisher Scientific (Pittsburgh, PA). Triethylamine and 17Aestradiol were obtained through Sigma Chemical Company (St. Louis, MO). All drugs and reagents were stored as indicated by the manufacturer.
Tissue culture
MCF-7 cells were purchased from the American Type Culture Collection (Manassas, VA). The MTag-34 cell line was derived from a mammary tumor excised from an MTag.Tg animal. All cells were grown in improved minimum essential medium (Invitrogen, Carlsbad, CA) without antibiotics and were supplemented with 10% fetal bovine serum. Cells were maintained in an atmosphere of 5% CO 2 /95% air at 37-C. Cells were propagated in 75-cm 2 tissue cultureYtreated flasks (Corning, Corning, NY) and were passaged at least once a week.
In vitro drug treatments
Stock solutions of ospemifene and 4-OH ospemifene were prepared by dissolution in dimethylsulfoxide (DMSO) followed by ethanol (EtOH) and were brought up to volume in sterile normal saline immediately before use. MTag-34 cells were treated with four concentrations of ospemifene or 4-OH ospemifene (0.01, 0.1, 1.0, and 6.6 KM). For the control, sterile saline (drug diluent) was added to the cell cultures in equivalent volumes. The final concentration of DMSO and ethanol in all flasks was 0.0083% and 0.15%, respectively. Cells were harvested when controls reached approximately 70% confluency and were trypsinized for the trypan blue dye exclusion assay. Trypsinized cells from each treatment condition were diluted in trypan blue and counted on a T4 Auto Cellometer (Nexcelom Bioscience, Lawrence, MA). Growth inhibition/stimulation was calculated as a percentage of the control.
Flow cytometry
Cells were trypsinized, pelleted, and resuspended in 1Â phosphate-buffered saline (PBS). Cells were transferred dropwise into a polystyrene tube containing ice-cold 70% EtOH. Tubes were stored at j20-C for at least 2 hours. Next, cells were pelleted, washed once in PBS, and resuspended in PBS and 10 Kg/mL DNase-free RNaseA. Tubes were incubated in a 37-C waterbath for 45 minutes. Propidium iodide was added to a concentration of 10 mg/mL followed by a 10-minute incubation at room temperature protected from light. Samples were analyzed on a Becton Dickinson Fortessa (BD, San Jose, CA) flow cytometer, and data were analyzed using ModFit software (Verity Software House, Topsham, ME).
Western blotting
Cells were lysed immediately in immunoprecipitation (IP) lysis buffer (Pierce IP Lysis Buffer; Thermo Scientific #8778) and stored until protein quantitation and Western blotting were performed. Protein lysates (45 Kg) were separated in precast 4% to 15% gradient sodium dodecyl sulfate polyacrylamide gel electrophoresis gels (BioRad 456-1083) and were transferred onto 0.2-Km polyvinylidene difluoride membranes (BioRad 162-0174). The following antibodies were used to assess protein expression: ER-> (E115; Novus Biologicals NB110-56961 lot#YF112101C, 1:1500), ER-A (Abcam, ab3576, lot#GR14900-1, 1:1500), and A-actin (AC-15; Sigma A5441, 1:50,000). All images were obtained on a FluorChem E System with AlphaView (SA) software, version 3.2.2 (Cell Biosciences, Santa Clara, CA).
High-performance liquid chromatography (HPLC)
Ospemifene and 4-OH ospemifene levels in the tumors and plasma of MTag.Tg mice were quantified as previously described. 35 Briefly, a Beckman (Fullerton, CA) model 320 gradient liquid chromatograph, a model 420 controller, two model 110A pumps along with a Whatman (Clifton, NJ), 5-Km reverse phase C18 Partisphere RTF 4.6 Â 250-mm column, 100-KL injection loop, and a Rheodyne injector were used to analyze the samples. Photochemically activated ospemifene, 4-OH ospemifene, and an internal standard (toremifene) were detected with a Linear Instruments model LC305 (Thermo-Finnigan, San Jose, CA) fluorescence detector set at an excitation wavelength of 266 nm and an emission wavelength of 370 nm. Peak height ratios of ospemifene and 4-OH ospemifene to internal standard were then calculated, and linear regression analysis of the data yielded the slope, y-intercept, and correlation coefficient of each standard curve.
Immunohistochemistry
Hematoxylin and eosin (H&E) and ER-> staining were carried out using standard protocols. For H&E staining, slides were cleared with xylene three times for 2 minutes each, hydrated with 100% to 70% EtOH in five steps at 2 minutes each, and rinsed with tap water for at least 2 minutes. Staining was carried out with hematoxylin for 3 minutes and eosin for 2 minutes. Slides were then dehydrated in 95% to 100% EtOH for 20 dips, followed by three 2-minute incubations. Finally, slides were cleared with three 2-minute washes in xylene and were coverslipped.
For ER staining, ER-> antibody from Santa Cruz (MC 20; Cat #sc542) was used. Slides were deparaffinized in three changes of xylene for 5 minutes each, followed by three changes of 100% EtOH for 2 minutes each. Endogenous peroxidase was quenched with hydrogen peroxide/methanol 20:180 mL for 30 minutes. Two changes of 100% EtOH, one 95% EtOH and one 70% EtOH for 2 minutes each, followed. Slides were hydrated for 5 minutes in running tap water and rinsed in distilled water for 2 minutes. Antigen retrieval was performed using freshly made citrate buffer, pH 6.0, in a decloaker. Slides were next rinsed in warm tap water for 5 minutes. Two PBS rinses for 5 minutes each preceded a blocking step for 20 minutes with 10% normal horse serum, diluted in PBS. Two PBS rinses for 5 minutes each followed the secondary antibody incubation, which was diluted in PBS + ovalbumin and incubated for 1 hour at room temperature. Two PBS rinses for 5 minutes each followed. Next, slides were incubated with avidin-biotin complex diluted in PBS + ovalbumin for 30 minutes at room temperature followed by two PBS rinses for 5 minutes each. Slides were exposed to diaminobenzidine (made in distilled water) for 1 to 5 minutes depending on the development and were rinsed in tap water for 5 minutes. Slides were counterstained for 10 to 20 seconds if antigen was nuclear and 30 seconds if antigen was cytoplasmic or on cell membrane. Slides were rinsed in tap water for 5 minutes to Bblue[ them. Finally, slides were dehydrated in 70% to 100% EtOH for 2 minutes each followed by three changes of xylene for 5 minutes each and were coverslipped.
Animal studies
Polyomavirus middle-T transgenic male founder mice were obtained from the Mayo Clinic (Scottsdale, AZ). All mice were supplied by our breeding colony maintained by the University of California (UC) Davis Mouse Biology Program and housed at the UC Davis Center for Laboratory Animal Science vivarium. The mice were kept in rooms maintained at constant temperature and humidity with a 12-hour light/12-hour dark cycle. All mice had free access to water and Purina Laboratory Rodent Diet (LabDiet 5001; PMI Nutrition International, St. Louis, MO). Animal studies were conducted under a protocol approved by the UC Davis Institutional Animal Care and Use Administrative Advisory Committee. UC Davis is an Association for Assessment and Accreditation of Laboratory Animal CareYaccredited institution. For genotyping, toe clippings from 2-week-old mice were placed in a 96-well plate. Next, 40 KL of 50 mM NaOH was added to each well, and the plates were heated to 94-C for 10 minutes. Extracted DNA was neutralized with 20 KL of 1 M Tris (pH 8) per well. The plates were sealed, vortexed briefly, centrifuged (6,000 rpm Â 2 min), and stored at j20-C until use. Polymerase chain reaction was used to identify MTag.Tg mice using an ABI Prism 7900HT Sequence Detection System (AB Applied Biosystems, Carlsbad, CA). MTag forward and reverse primers were 5 ¶-TTGGAG AATGTTTTTGTCTTGAATG and 3 ¶-CAGCACATCTCGG GTTGGT. The MTag TaqMan probe (ACATGCAATGGT TTGGAA) carrying a 6 ¶ fluoresceinamidite reporter label and a 3 ¶ minor groove binder non fluorescent quencher group was used. The amplification program consisted of one cycle of 2 minutes at 95-C and 40 cycles of 15 seconds each at 60-C and 95-C.
In vivo drug treatments Prevention study
Female 4-to 6-week-old MTag.Tg C57BL/6 mice weighing approximately 12 g were assigned to four treatment groups: control (n = 7) and ospemifene 5 mg/kg (n = 7), 25 mg/kg (n = 8), and 50 mg/kg (n = 8). Ospemifene doses were calculated weekly using weight data. Ospemifene was dissolved in DMSO and then brought up to volume in peanut oil, yielding final concentrations of ospemifene that would deliver 5, 25, and 50 mg/kg doses in a volume of 100 KL. Control solution consisted of 2% DMSO in peanut oil. The final concentration of DMSO in all solutions was 2%. Ospemifene and control solutions were orally administered daily by gavage according to treatment group. The mice were evaluated weekly for changes in weight and the development of mammary tumors. Tumors were palpated and, when possible, measured using calipers to assess tumor volume. Approximate tumor volumes were calculated using the formula v = l Â w Â h, where v is the volume, w is the width, h is the height, and l is the length of the tumor. Once tumors reached 1.5 cm 3 , or the mouse had an abscessed tumor, was visibly in pain, or was unable to ambulate, animals were killed in a CO 2 chamber. Upon euthanization, the whole blood was collected by cardiac puncture into heparinized tubes, and the tissues were harvested for HPLC analysis. A portion of each tumor was preserved in buffered 4% formalin, followed by 70% EtOH storage and paraffin embedding for histological analyses.
Treatment study
Four-week-old MTag.Tg C57BL/6 mice that weighed approximately 16 g were allowed to develop breast cancer for 16 weeks unperturbed. At this time, the mice were sorted to achieve equal average weights and tumor volumes in each treatment group. The average weight of all groups was approximately 22 g. Ospemifene doses were calculated using weekly weight data, and dosing solutions were prepared and administered as described in the BPrevention study[ subsection. As in this subsection, the treatment groups consisted of control and ospemifene 5, 25, and 50 mg/kg (n = 10, all groups). The mice were evaluated weekly for changes in weight and the development of mammary tumors. Tumors were palpated, and when possible, measured using calipers to assess tumor volume. Approximate tumor volumes were calculated as described in the BPrevention study[ subsection. As in this section, once tumors reached 1.5 cm 3 , or the mouse had an abscessed tumor, was visibly in pain, or was unable to ambulate, animals were killed in a CO 2 chamber. Upon euthanization, whole blood and tissues were collected and processed as described in the BPrevention study[ subsection.
Statistical analysis
Differences in average tumor volume between experimental groups were evaluated for statistical significance using a one-way analysis of variance test. A P value of 0.05 or less was considered significant. Kaplan-Meier survival curves and log-rank test for significance were generated by GraphPad (La Jolla, CA) Prism 5 software.
RESULTS
MTag.Tg tumors and a derived cell line are ER positive
The MTag.Tg mouse breast cancer model involves the directed expression of the polyomavirus middle-T antigen fusion gene in the mammary tissue of C57BL/6 mice. 36 This expression leads to rapid and early transformation of the mammary tissue in all 10 fat pads of an animal. 36 This model's progression of cancer has been shown to parallel the development of human mammary cancers, both histologically and biologically. 36, 37 To examine the ER status and potential antiestrogen sensitivity of the MTag.Tg tumors, the mice were allowed to develop tumors, which were then prepared for immunohistochemical staining and Western blotting. Figure 1A shows the representative H&E staining, whereas Figure 1B shows the ER-> expression patterns in an MTag.Tg tumor. A cell line established from an MTag.Tg tumor (MTag-34) shows the preservation of the same protein expression patterns of ER-> and ER-A in vitro (see Fig. 1C for Western blotting data).
Ospemifene and 4-OH ospemifene treatments do not stimulate the growth of the MTag.Tg cell line in vitro
To test the in vitro effect of ospemifene on the MTag-34 cell line, cells were treated with four concentrations of ospemifene or its active metabolite 4-OH ospemifene and were harvested for the trypan blue dye exclusion assay and cell counts when controls reached approximately 70% confluence. The results shown in Figure 2A demonstrate that ospemifene did not significantly affect cell growth at 4 days, as it previously did in the MCF-7 human breast cancer cell line, which is known to be sensitive to antiestrogens. 38 When MTag-34 cells were treated with 4-OH ospemifene, similar results were observed. These treated cells were analyzed for DNA content, and flow cytometric data did not indicate a cell cycle arrest (data not shown). When cells were plated at a lower confluency and continuously exposed for 7 days, the same results were observed.
These data led us to conclude that neither ospemifene nor its major metabolite stimulated the growth of the MTag.Tg-derived tumor cell line and that these compounds may indeed delay the development or progression of breast cancer in the context of the MTag.Tg background given continuous exposure.
Ospemifene delays the development of breast cancer in vivo
To examine the effects of ospemifene in vivo, 31 4-weekold mice were separated into groups and administered control and 5-, 25-, or 50-mg/kg doses of ospemifene daily, by oral gavage. These doses were chosen based on previous work. 35, 38 The mice were weighed weekly and palpated for the presence of mammary tumors. Mice weights were not significantly affected in any treatment group. Tumors were measured in three dimensions, and the animals were killed when the maximal tumor burden was reached. Ospemifene and its metabolite 4-OH ospemifene were quantified in the plasma and tumors of each animal to confirm dosing levels in this model. Table 1A shows the average plasma and tumor concentrations of ospemifene and 4-OH ospemifene in the tumors and plasma of all animals, as described in the BPrevention study[ subsection.
Observed plasma concentrations were similar to those found in humans at equivalent dose levels. 39 In the higher dosing groups, the average tumor concentrations of ospemifene were elevated compared with those observed in plasma, as previously observed. 15<27,38 The effects of ospemifene on tumor volumes were observed early in this study. The average tumor volumes at the emergence of the first measurable tumor are shown in Figure 3A . The average tumor volumes from the control mice were significantly larger than those of the 50-mg/kg group at this intermediate point. Figure 3B shows the survival curves produced from the different dose groups. No difference was observed between the control and 5-mg/kg treatment groups. The 25-mg/kg group did not reach significance compared with the control (P = 0.0787), but a trend was evident. In contrast, the animals in the highest dose group did gain a clear and significant survival advantage over controls (P = 0.0085).
Ospemifene treats breast cancer
To examine the impact of ospemifene in the treatment setting, 40 MTag.Tg mice were allowed to develop tumors for 16 weeks. At this time, the mice were sorted into four groups with equal weights and tumor burdens. The average tumor burden including all 10 tumor sites was approximately 300 mm 3 (297.3, 295.2, 295.1, and 301.8 mm 3 , respectively) in each group. The mice underwent daily gavage at the same four doses: control and 5, 25, or 50 mg/kg ospemifene until the maximal tumor volumes were reached. Table 1B shows the concentration of ospemifene and 4-OH ospemifene in the tumors and plasma from each animal in this study. Again, observed plasma concentrations were similar to those found in humans at equivalent dose levels. 39 Survival curves from this study are shown in Figure 4 . As seen previously, ospemifene treatment prolonged the average lifespan of mice in the 25-and 50-mg/kg treatment groups but, as in the BPrevention study[ subsection, was only significant at the 50-mg/kg dose (P = 0.0586 and 0.0143, respectively).
DISCUSSION
Ospemifene, an investigational SERM, was originally developed as an osteoporosis drug. It reduces bone turnover, increases bone strength, 40<42 and has a positive effect on serum lipids 41, 43 whereas cardiovascular surrogate markers remain neutral. 41 These bone effects are thought to be ER mediated. 44 Ospemifene exerts antiestrogenic effects on the breast tissue, as well as estrogen-like effects on the bone, serum lipids (lowering low-density lipoprotein), 41, 43 and the genitourinary tract. 45, 46 Ospemifene recently completed two phase III clinical trials, in addition to a long-term safety study, 47 and is a welltolerated treatment in development for VVA. Treatment with ospemifene results in relief of VVA symptoms compared with vaginal lubricants alone, improves most bothersome symptom, and decreases vaginal pH. 48 Ospemifene does not cause breast tenderness or aggravate vasomotor symptoms associated with menopause, such as hot flashes. 47 Its positive effects on VVA symptoms were sustained during a 1-year follow-up study. 49 Ospemifene does not carry with it the risks of thromboembolism or endometrial proliferative effects as estrogen does, 50, 51 but concerns regarding the treatment of women with a SERM demand the examination of its effects on the breast.
In previous studies, ospemifene prevented the growth of premalignant lesions and the progression to invasive carcinoma in the adenoma/mammary intraepithelial neoplasia mouse model 52 and slowed down the tumor growth of MCF-7 xenografts. 25 These models are not optimal to study drug treatment because the implantation of the adenoma/mammary intraepithelial neoplasia tissue is a surgical procedure, and the MCF-7 studies were carried out in ovariectomized nude mice. Neither group possessed intact or, otherwise, unperturbed immune systems. Ospemifene has also been shown to be effective in preventing the development of dimethylbenzanthracene chemically induced breast carcinomas in the Sencar mouse model, but in this case, the cancer was induced rather than arising without intervention. 35 An examination of the impact of ospemifene on breast cancer in an immune-intact, nonYchemically induced model was lacking.
The MTag.Tg model uses directed expression of the polyomavirus middle-T protein in mammary tissue to produce synchronized, multifocal tumors, which are pathologically very similar to the development of breast cancer in humans. 36, 37 This model has a short latency period and is pregnancy independent. Four distinct stages of disease can be observed. By 4 weeks, hyperplasia is already present, followed by the development of adenoma/mammary intraepithelial neoplasia at 8 weeks, with early and late carcinoma after that (8-9 and 8-12 wk, respectively). Tumors are initially ER positive and lose some expression over time. We show here that the MTag.Tg tumors and a derived cell line remain ER positive and respond to antiestrogen therapy. This is the first time such an antiestrogen study has been carried out in this model. MTag-34 cells treated with ospemifene and 4-OH ospemifene were not stimulated in vitro, and no impact on cell cycle was seen by flow cytometric analysis (data not shown). These data warranted further testing in our animal model, despite the lack of an antitumor effect in vitro. Ospemifene is a good example of how important in vivo testing is regardless of outcomes in vitro. Many effective hormonal therapies may be overlooked during the process of drug development due to their lack of short-term toxicity in vitro, while proving to be effective in vivo after metabolism and prolonged exposure at low doses. 53<55 Antiestrogenic therapies used in the treatment of women with breast cancer include tamoxifen, anastrozole, letrozole, and exemestane, which can cause sexual dysfunction and increased vasomotor symptoms. 56<58 Tamoxifen use increased FIG. 3. A: Tumors in the control group were significantly larger at first measurable than those in the highest dose of ospemifene. Tumor volumes at first measurable were averaged by group. No difference in the time to first palpable or measurable was observed. Asterisk indicates statistical significance at P G 0.05. B: Osp slows the progression of tumor growth in young MTag.Tg mice. Thirty-one MTag.Tg mice were grouped and treated with either control or three increasing doses of ospemifene (5, 25, or 50 mg/kg, respectively) and were palpated weekly for the presence of tumors. The mice were euthanized when tumor burden maximum was reached. The study was ended when 80% of the controls were lost. Osp, ospemifene.
reported rates of vaginal dryness and dyspareunia, 59 which were more severe than those experienced by untreated women, 10, 60 and these symptoms correlated with decreased libido, arousal, and ability to experience orgasm. 59, 61 Most women are still sexually active while being treated for breast cancer, 62, 63 and high noncompliance rates for women with breast cancer taking adjuvant tamoxifen and other antiestrogen therapy (up to 50% for tamoxifen use) may be partially attributed to the adverse effects including VVA. 64<66 In this study, ospemifene effectively treated and prevented breast cancer development in mice, suggesting that ospemifene could be developed as a breast cancer agent that does not carry the risks of VVA and other adverse effects associated with currently approved antiestrogenic therapies.
CONCLUSIONS
Ospemifene, a drug in the late stage of development for the treatment of women with VVA, does not seem to carry the risks of thromboembolism or clinically significant endometrial proliferative effects that have been associated with estrogen-based treatments. In the present study, we confirmed the results of previous studies showing that ospemifene does not exert an estrogenic effect in the breast and provides some protection against breast cancer in several animal models. Because of its pathological and physiological similarity to human breast cancer, the mouse model used in this study provides the best evidence yet that ospemifene may be an effective agent in treating women with breast cancer in both the adjuvant and preventive settings. These findings are even more important, given the strength of the MTag.Tg model's oncogene. In a postmenopausal woman, ospemifene may have an even greater impact on breast cancer risk. MTag.Tg mice were allowed to develop tumors for 16 weeks. At this time, the mice were grouped to achieve equal average weights and tumor volumes and were treated with either control or three increasing doses of Osp (5, 25, or 50 mg/kg, respectively). The mice were palpated weekly for the presence of tumors. The mice were euthanized when tumor burden maximum was reached. The study was ended when 80% of the controls were lost. Osp, ospemifene.
